{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:18:32Z","timestamp":1753355912363},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,20]]},"DOI":"10.7759\/cureus.12797","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:23:55Z","timestamp":1611141835000},"source":"Crossref","is-referenced-by-count":3,"title":["Systemic Sclerosis: Current State and Survival After Lung Transplantation"],"prefix":"10.7759","author":[{"given":"Artem","family":"Minalyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilit","family":"Gabrielyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shristi","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bikash","family":"Basyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Derk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2007.11.001","article-title":"Scleroderma-like fibrosing disorders","volume":"34","author":"Boin F","year":"2008","unstructured":"Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008, 34:199-220. 10.1016\/j.rdc.2007.11.001","journal-title":"Rheum Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli A","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009, 360:1989-2003. 10.1056\/NEJMra0806188","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski V","year":"2019","unstructured":"Sobanski V, Giovannelli J, Allanore Y, et al.. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis. Arthritis Rheumatol. 2019, 71:1553-1570. 10.1002\/art.40906","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco A","year":"2019","unstructured":"Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019, 11:257-273. 10.2147\/CLEP.S191418","journal-title":"Clin Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick AL","year":"2005","unstructured":"Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). 2005, 44:587-596. 10.1093\/rheumatology\/keh552","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.04.011","article-title":"Musculoskeletal manifestations of systemic sclerosis","volume":"41","author":"Morrisroe KB","year":"2015","unstructured":"Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal manifestations of systemic sclerosis. Rheum Dis Clin North Am. 2015, 41:507-518. 10.1016\/j.rdc.2015.04.011","journal-title":"Rheum Dis Clin North Am"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4977-8","article-title":"Intestinal involvement in systemic sclerosis: a clinical review","volume":"63","author":"Sakkas LI","year":"2018","unstructured":"Sakkas LI, Simopoulou T, Daoussis D, Liossis SN, Potamianos S. Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci. 2018, 63:834-844. 10.1007\/s10620-018-4977-8","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283588dcf","article-title":"Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management","volume":"24","author":"Shanmugam VK","year":"2012","unstructured":"Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012, 24:669-676. 10.1097\/BOR.0b013e3283588dcf","journal-title":"Curr Opin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v6.i9.993","article-title":"Cardiac manifestations in systemic sclerosis","volume":"6","author":"Lambova S","year":"2014","unstructured":"Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol. 2014, 6:993-1005. 10.4330\/wjc.v6.i9.993","journal-title":"World J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2606w","article-title":"Systemic sclerosis and malignancy: a review of current data","volume":"8","author":"Zeineddine N","year":"2016","unstructured":"Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res. 2016, 8:625-632. 10.14740\/jocmr2606w","journal-title":"J Clin Med Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000551","article-title":"Mortality and survival in systemic sclerosis: a review of recent literature","volume":"30","author":"Poudel DR","year":"2018","unstructured":"Poudel DR, Derk CT. Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol. 2018, 30:588-593. 10.1097\/BOR.0000000000000551","journal-title":"Curr Opin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen VD","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007, 66:940-944. 10.1136\/ard.2006.066068","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.05.001","article-title":"Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease","volume":"40","author":"Perelas A","year":"2019","unstructured":"Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019, 40:501-518. 10.1016\/j.ccm.2019.05.001","journal-title":"Clin Chest Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova SI","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, et al.. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014, 66:1625-1635. 10.1002\/art.38390","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone TA","year":"2014","unstructured":"Winstone TA, Assayag D, Wilcox PG, et al.. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014, 146:422-436. 10.1378\/chest.13-2626","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-426FR","article-title":"Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies","volume":"13","author":"Volkmann ER","year":"2016","unstructured":"Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc. 2016, 13:2045-2056. 10.1513\/AnnalsATS.201606-426FR","journal-title":"Ann Am Thorac Soc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin DP","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al.. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006, 354:2655-2666. 10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-719. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich O","year":"2006","unstructured":"Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25:205-212. 10.1007\/s10067-005-1157-y","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna D","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al.. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016, 387:2630-2640. 10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis D","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, et al.. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010, 49:271-280. 10.1093\/rheumatology\/kep093","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler O","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al.. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019, 380:2518-2528. 10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna D","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, et al.. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016, 43:1672-1679. 10.3899\/jrheum.151322","journal-title":"J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0056-2017","article-title":"Pulmonary hypertension in systemic sclerosis: different phenotypes","volume":"26","author":"Launay D","year":"2017","unstructured":"Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017, 26:170056. 10.1183\/16000617.0056-2017","journal-title":"Eur Respir Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31818193bb","article-title":"Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology","volume":"87","author":"Montani D","year":"2008","unstructured":"Montani D, Achouh L, Dorfm\u00fcller P, et al.. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008, 87:220-233. 10.1097\/MD.0b013e31818193bb","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau G","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, et al.. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019, 53:1801913. 10.1183\/13993003.01913-2018","journal-title":"Eur Respir J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007810","article-title":"Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management","volume":"19","author":"Hachulla E","year":"2010","unstructured":"Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev. 2010, 19:314-320. 10.1183\/09059180.00007810","journal-title":"Eur Respir Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.03.025","article-title":"Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)","volume":"126","author":"Shapiro S","year":"2017","unstructured":"Shapiro S, Torres F, Feldman J, et al.. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med. 2017, 126:84-92. 10.1016\/j.rmed.2017.03.025","journal-title":"Respir Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8 N","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al.. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015, 373:834-844. 10.1056\/NEJMoa1413687","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon O","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al.. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015, 373:2522-2533. 10.1056\/NEJMoa1503184","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill D","year":"2015","unstructured":"Weill D, Benden C, Corris PA, et al.. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015, 34:1-15. 10.1016\/j.healun.2014.06.014","journal-title":"J Heart Lung Transplant"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90681-5","article-title":"Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension","volume":"73","author":"Kramer MR","year":"1994","unstructured":"Kramer MR, Valantine HA, Marshall SE, Starnes VA, Theodore J. Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol. 1994, 73:494-500. 10.1016\/0002-9149(94)90681-5","journal-title":"Am J Cardiol"},{"key":"ref33","article-title":"Lung transplantation and systemic sclerosis","volume":"5","author":"Rosas V","year":"2000","unstructured":"Rosas V, Conte JV, Yang SC, et al.. Lung transplantation and systemic sclerosis. Ann Transplant. 2000, 5:38-43.","journal-title":"Ann Transplant"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139809","article-title":"Systemic sclerosis and bilateral lung transplantation: a single centre experience","volume":"36","author":"Saggar R","year":"2010","unstructured":"Saggar R, Khanna D, Furst DE, et al.. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J. 2010, 36:893-900. 10.1183\/09031936.00139809","journal-title":"Eur Respir J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.00958.x","article-title":"Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation","volume":"23","author":"Shitrit D","year":"2009","unstructured":"Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, Kramer MR. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009, 23:178-183. 10.1111\/j.1399-0012.2009.00958.x","journal-title":"Clin Transplant"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182845f23","article-title":"Outcomes in systemic sclerosis-related lung disease after lung transplantation","volume":"95","author":"Sottile PD","year":"2013","unstructured":"Sottile PD, Iturbe D, Katsumoto TR, et al.. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013, 95:975-980. 10.1097\/TP.0b013e3182845f23","journal-title":"Transplantation"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2014.01.020","article-title":"Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group","volume":"43","author":"Launay D","year":"2014","unstructured":"Launay D, Savale L, Berezne A, et al.. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Med. 2014, 43:e345-e363. 10.1016\/j.lpm.2014.01.020","journal-title":"Presse Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes","volume":"13","author":"Crespo MM","year":"2016","unstructured":"Crespo MM, Bermudez CA, Dew MA, et al.. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc. 2016, 13:784-792. 10.1513\/AnnalsATS.201503-177OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201512-806OC","article-title":"Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience","volume":"13","author":"Miele CH","year":"2016","unstructured":"Miele CH, Schwab K, Saggar R, et al.. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc. 2016, 13:793-802. 10.1513\/AnnalsATS.201512-806OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref40","article-title":"Lung transplantation in scleroderma: one centre's experience","volume":"1","author":"S. Pakhale","year":"2002","unstructured":"S. Pakhale, L. Singer, C. Chaparro, et al.. Lung transplantation in scleroderma: one centre's experience. Am J Respir Crit Care Med. 2002, 1:3-5.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s1053-2498(00)00349-1","article-title":"Lung transplantation in patients with scleroderma","volume":"20","author":"Kubo M","year":"2001","unstructured":"Kubo M, Vensak J, Dauber J, Keenan R, Griffith B, McCurry K. Lung transplantation in patients with scleroderma. J Heart Lung Transplant. 2001, 20:174-175. 10.1016\/s1053-2498(00)00349-1","journal-title":"J Heart Lung Transplant"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.01.858","article-title":"Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation","volume":"33","author":"Yazdani A","year":"2014","unstructured":"Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014, 33:514-520. 10.1016\/j.healun.2014.01.858","journal-title":"J Heart Lung Transplant"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2016.0209","article-title":"Lung or heart-lung transplant in pulmonary arterial hypertension: what is the impact of systemic sclerosis?","volume":"15","author":"Gadre SK","year":"2017","unstructured":"Gadre SK, Minai OA, Wang XF, Zhang Q, Budev M, Tonelli AR. Lung or heart-lung transplant in pulmonary arterial hypertension: what is the impact of systemic sclerosis?. Exp Clin Transplant. 2017, 15:676-684. 10.6002\/ect.2016.0209","journal-title":"Exp Clin Transplant"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-0939.2017.10.007","article-title":"Lung transplantation for connective tissue disease-associated interstitial lung disease recipient (Article in Chinese)","volume":"40","author":"Zhang J","year":"2017","unstructured":"Zhang J, Wu B, Zhou M, et al.. Lung transplantation for connective tissue disease-associated interstitial lung disease recipient (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi. 2017, 40:744-748. 10.3760\/cma.j.issn.1001-0939.2017.10.007","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2017.09.038","article-title":"Long-term survival in bilateral lung transplantation for scleroderma-related lung disease","volume":"105","author":"Chan EY","year":"2018","unstructured":"Chan EY, Goodarzi A, Sinha N, et al.. Long-term survival in bilateral lung transplantation for scleroderma-related lung disease. Ann Thorac Surg. 2018, 105:893-900. 10.1016\/j.athoracsur.2017.09.038","journal-title":"Ann Thorac Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna L","year":"2006","unstructured":"Schachna L, Medsger TA Jr, Dauber JH, et al.. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006, 54:3954-3961. 10.1002\/art.22264","journal-title":"Arthritis Rheum"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0017-x","article-title":"Outcomes of lung transplantation in patients with scleroderma","volume":"29","author":"Massad MG","year":"2005","unstructured":"Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, Geha AS. Outcomes of lung transplantation in patients with scleroderma. World J Surg. 2005, 29:1510-1515. 10.1007\/s00268-005-0017-x","journal-title":"World J Surg"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein EJ","year":"2015","unstructured":"Bernstein EJ, Peterson ER, Sell JL, D'Ovidio F, Arcasoy SM, Bathon JM, Lederer DJ. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015, 67:1314-1322. 10.1002\/art.39021","journal-title":"Arthritis Rheumatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Prad\u00e8re P","year":"2018","unstructured":"Prad\u00e8re P, Tudorache I, Magnusson J, et al.. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Heart Lung Transplant. 2018, 37:903-911. 10.1016\/j.healun.2018.03.003","journal-title":"J Heart Lung Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/49349-systemic-sclerosis-current-state-and-survival-after-lung-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:12Z","timestamp":1707507192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/49349-systemic-sclerosis-current-state-and-survival-after-lung-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.12797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}